Cargando…
The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials
BACKGROUND: The evidence base for the widely accepted standard regimen of succinylcholine for rapid sequence induction (1.0 mg kg(− 1)) remains unclear. METHODS: We performed a systematic review and meta-analysis of randomized trials comparing any succinylcholine regimen with the standard regimen (1...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053066/ https://www.ncbi.nlm.nih.gov/pubmed/32122305 http://dx.doi.org/10.1186/s12871-020-00968-1 |
_version_ | 1783502965698461696 |
---|---|
author | Putzu, Alessandro Tramèr, Martin R. Giffa, Maxim Czarnetzki, Christoph |
author_facet | Putzu, Alessandro Tramèr, Martin R. Giffa, Maxim Czarnetzki, Christoph |
author_sort | Putzu, Alessandro |
collection | PubMed |
description | BACKGROUND: The evidence base for the widely accepted standard regimen of succinylcholine for rapid sequence induction (1.0 mg kg(− 1)) remains unclear. METHODS: We performed a systematic review and meta-analysis of randomized trials comparing any succinylcholine regimen with the standard regimen (1.0 mg kg(− 1)) and reporting on intubating conditions and/or apnoea times. Results were expressed as absolute risk differences (ARD) for dichotomous data and mean differences (MD) for continuous data. RESULTS: We retrieved six trials with relevant data of 864 patients (ASA 1 or 2, aged 18–65 years, body mass index < 30 kg m(− 2)). Four regimens (0.3, 0.4, 0.5, 0.6 mg kg(− 1)) were compared with 1.0 mg kg(− 1) in at least three trials each, and three (0.8, 1.5, 2 mg kg(− 1)) in one each. With 0.3 to 0.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly decreased (ARD − 22% to − 67%). With 0.3 and 0.4 mg kg(− 1), but not with 0.5, 0.6, 0.8, 1.5 and 2.0 mg kg(− 1), the likelihood of unacceptable intubating conditions was significantly increased (ARD + 22% and + 32%, respectively). With 2.0 mg kg(− 1), but not with 0.8 or 1.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly increased (ARD + 23%). Apnoea times were significantly shorter with regimens ≤0.8 mg kg(− 1) (MD − 1.0 to − 3.4 min) but were not reported with 1.5 or 2.0 mg kg(− 1). CONCLUSIONS: With succinylcholine regimens ≤0.5 mg kg(− 1), excellent intubating conditions are less likely and apnoea times are shorter, compared with 1 mg kg(− 1). With 0.3 and 0.4 mg kg(− 1), unacceptable intubating conditions are more common. Succinylcholine 1.5 mg kg(− 1) does not produce more often excellent conditions compared with 1 mg kg(− 1), while 2.0 mg kg(− 1) does, but the database with these regimens is weak and apnoea times remain unknown. Limited information size and strong statistical heterogeneity decrease the certainty of the evidence. |
format | Online Article Text |
id | pubmed-7053066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70530662020-03-10 The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials Putzu, Alessandro Tramèr, Martin R. Giffa, Maxim Czarnetzki, Christoph BMC Anesthesiol Research Article BACKGROUND: The evidence base for the widely accepted standard regimen of succinylcholine for rapid sequence induction (1.0 mg kg(− 1)) remains unclear. METHODS: We performed a systematic review and meta-analysis of randomized trials comparing any succinylcholine regimen with the standard regimen (1.0 mg kg(− 1)) and reporting on intubating conditions and/or apnoea times. Results were expressed as absolute risk differences (ARD) for dichotomous data and mean differences (MD) for continuous data. RESULTS: We retrieved six trials with relevant data of 864 patients (ASA 1 or 2, aged 18–65 years, body mass index < 30 kg m(− 2)). Four regimens (0.3, 0.4, 0.5, 0.6 mg kg(− 1)) were compared with 1.0 mg kg(− 1) in at least three trials each, and three (0.8, 1.5, 2 mg kg(− 1)) in one each. With 0.3 to 0.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly decreased (ARD − 22% to − 67%). With 0.3 and 0.4 mg kg(− 1), but not with 0.5, 0.6, 0.8, 1.5 and 2.0 mg kg(− 1), the likelihood of unacceptable intubating conditions was significantly increased (ARD + 22% and + 32%, respectively). With 2.0 mg kg(− 1), but not with 0.8 or 1.5 mg kg(− 1), the likelihood of excellent intubating conditions was significantly increased (ARD + 23%). Apnoea times were significantly shorter with regimens ≤0.8 mg kg(− 1) (MD − 1.0 to − 3.4 min) but were not reported with 1.5 or 2.0 mg kg(− 1). CONCLUSIONS: With succinylcholine regimens ≤0.5 mg kg(− 1), excellent intubating conditions are less likely and apnoea times are shorter, compared with 1 mg kg(− 1). With 0.3 and 0.4 mg kg(− 1), unacceptable intubating conditions are more common. Succinylcholine 1.5 mg kg(− 1) does not produce more often excellent conditions compared with 1 mg kg(− 1), while 2.0 mg kg(− 1) does, but the database with these regimens is weak and apnoea times remain unknown. Limited information size and strong statistical heterogeneity decrease the certainty of the evidence. BioMed Central 2020-03-02 /pmc/articles/PMC7053066/ /pubmed/32122305 http://dx.doi.org/10.1186/s12871-020-00968-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Putzu, Alessandro Tramèr, Martin R. Giffa, Maxim Czarnetzki, Christoph The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials |
title | The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials |
title_full | The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials |
title_fullStr | The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials |
title_full_unstemmed | The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials |
title_short | The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials |
title_sort | optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053066/ https://www.ncbi.nlm.nih.gov/pubmed/32122305 http://dx.doi.org/10.1186/s12871-020-00968-1 |
work_keys_str_mv | AT putzualessandro theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials AT tramermartinr theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials AT giffamaxim theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials AT czarnetzkichristoph theoptimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials AT putzualessandro optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials AT tramermartinr optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials AT giffamaxim optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials AT czarnetzkichristoph optimaldoseofsuccinylcholineforrapidsequenceinductionasystematicreviewandmetaanalysisofrandomizedtrials |